Radiation Exposure and Safety of Lymphatic Mapping and Selective (Sentinel) Lymph Node Biopsy Procedures for Melanoma and Breast Cancer Treatment

Not Applicable

Completed

• Conditions: Early Stage I/II Melanoma; Breast Cancer; Cancer - Breast

• Registration Number: ACTRN12605000428662
• Lead Sponsor: Royal Adelaide Hospital/University of Adelaide

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Stage I and II cutaneous melanoma > 1mm in Breslow thickness or > Clark Level III; Stage I and II Breast Cancer; Absence of Metastases; Informed Consent.

Exclusion Criteria

Pregnancy; Other malignancy.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine exposure during Selective (Sentinel) Lymph Node Biopsy procedures[Evaluated during and for 24 hours after the procedures.];To determine safety during Selective (Sentinel) Lymph Node Biopsy procedures[Evaluated during and for 24 hours after the procedures.]

Secondary Outcome Measures

Name	Time	Method
The secondary outcome was to determine possible associations between procedure duration and handling, exposure level and safety.[]